1. Cardiovascular outcomes in patients who experienced a myocardial infarction while treated with liraglutide versus placebo in the LEADER trial. (September 2018) Authors: Nauck, Michael A; Tornøe, Karen; Rasmussen, Søren; Treppendahl, Marianne Bach; Marso, Steven P Journal: Diabetes & vascular disease research Issue: Volume 15:Number 5(2018:Sep.) Page Start: 465 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial. Issue 9 (September 2021) Authors: Neeland, Ian J; Marso, Steven P; Ayers, Colby R; Lewis, Bienka; Oslica, Robert; Francis, Wynona; Rodder, Susan; Pandey, Ambarish; Joshi, Parag H Journal: Lancet Issue: Volume 9:Issue 9(2021) Page Start: 595 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1–7 randomised controlled trials. Issue 11 (November 2020) Authors: Mann, Johannes F E; Hansen, Thomas; Idorn, Thomas; Leiter, Lawrence A; Marso, Steven P; Rossing, Peter; Seufert, Jochen; Tadayon, Sayeh; Vilsbøll, Tina Journal: Lancet Issue: Volume 8:Issue 11(2020) Page Start: 880 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗